2024-至今(Date)福州大学化学学院，副教授、硕导。

Associate Professor, Master Advisor, College of Chemistry, Fuzhou University.

2019-2024清华大学清华-伯克利深圳学院，工学博士。

Ph.D., Tsinghua-Berkeley Shenzhen Institute, Tsinghua University.

2015-2019，华中科技大学生命科学与技术学院，理学学士。

B.Sc., College of Life Science and Technology, Huazhong University of Science and Technology.

主要从事生物医学领域研究，简要包括：肿瘤靶向治疗、新型肿瘤治疗靶点挖掘、新型光敏剂开发、肿瘤光动力治疗、光动力抗菌。

Ploughing the field of biomedicine, briefly including: tumor targeted therapy, identification of novel oncotherapeutic targets, development of novel photosensitizer, photodynamic oncotherapy, anti-bacteria photodynamic therapy.

福州大学科研启动基金Startup Funding of Fuzhou University

1.Huang P, Wolde T, Bhardwaj V, Zhang X, and Pandey V. TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy.Life Sciences. 2024, 357:123113.

2.Huang P, Zhang X, Prabhu JS, and Pandey V. Therapeutic vulnerabilities in triple negative breast cancer: stem-like traits explored within molecular classification.Biomedicine & Pharmacotherapy. 2024, 147:116584.

3.Wolde T, Huang J,Huang P, Pandey V, and Qin PW. Depleted-MLH1 expression predicts prognosis and immunotherapeutic efficacy in uterine corpus endometrial cancer: an in silico approach.BioMedInformatics. 2024, 4:326-346.

4.Zhang X, Wang LQ, Chen S,Huang P, Ma L, Ding H, Basappa B, Zhu T, Lobie PE, and Pandey V. Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.Communications medicine. 2022, 2:82.

Zhang X,Huang P^(co-primary), Wang LQ, Chen S, Basappa B, Zhu T, Lobie PE, and Pandey V. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.Cell death & disease. 2022, 12:558.